bit.bio
PrivateLast Round
Series D
Nov 4, 2026
Est. Valuation
$500M
Total Funding Raised
$253.92M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
bit.bio operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series D round in November 2026.
bit.bio is a biotechnology company that provides human cells for research, drug discovery and cell therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
bit.bio Comparables
Compare bit.bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iXCells Biotechnologies | 82% | |
| BrainXell | 82% | |
| Axol Bioscience | 81% |
For institutional investors. Book with your work email.
bit.bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 4, 2026 | ||||
| Series C | Jan 9, 2026 | ||||
| Growth Equity | Dec 16, 2024 | ||||
| Series B | Nov 5, 2021 | ||||
| Series A | Jun 13, 2020 | ||||
Seed | Mar 27, 2019 |
For institutional investors. Book with your work email.
bit.bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Metaplanet Holdings | Series B |
| BlueYard Capital | Series A, Growth Equity |
| Prudential Assurance Company | Series C |
| ARCH Venture Partners | Growth Equity, Series A, Series B |
| M&G Investments | Series D, Series C, Growth Equity |
| Foresite Capital | Series B, Series A |
| Puhua Capital | Series B, Growth Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 4, 2026
$25M round with M&G Investments and Dr. Jonathan Milner.
- Dec 2, 2025
Received Platinum status in the Green Impact Awards for the second consecutive year.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 4, 2026
Bit Bio Ltd closes a $25M Series D round with participation from existing investor M&G Investments and Dr Jonathan Milner to expand its human cell model portfolio and increase access to its technology.
- partners_withSep 23, 2026
On Sep 23rd '26, United Kingdom-based Bit Bio Ltd partnered with Myriamed to advance human-relevant research and drug discovery by making high-quality, functional human heart cells more accessible to researchers.
- launchesAug 15, 2026
Bit Bio Ltd launches ioScreen, a CRISPR screening service designed to accelerate human cell-based drug discovery.
For institutional investors. Book with your work email.
bit.bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about bit.bio's valuation, stock price, and market status.
Is bit.bio a public or private company?
bit.bio is a private company.
What is the current stock price of bit.bio?
bit.bio is a private company, so its shares have no public market price. Caplight tracks bit.bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is bit.bio worth (valuation)?
bit.bio's valuation is estimated at $500.0M based on funding round data.
Can I buy bit.bio stock?
bit.bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was bit.bio's last funding round?
bit.bio's most recent funding round was Series D on November 4, 2026.
Who are the main investors in bit.bio?
Key investors in bit.bio include Prudential Assurance Company, ARCH Venture Partners, M&G Investments, Foresite Capital.
Will bit.bio IPO soon?
No public IPO plans have been announced for bit.bio.
How can I track bit.bio secondary market activity?
Caplight tracks bids, offers, and trades in bit.bio's shares on secondary markets.